ZAMBIA MEDICINES REGULATORY AUTHORITY

PRESS STATEMENT

(FOR IMMEDIATE RELEASE)

STATEMENT BY THE DIRECTOR GENERAL OF THE ZAMBIA MEDICINES REGULATORY AUTHORITY (ZAMRA), MR MAKOMANI SIYANGA, ON THE APPOINTMENT OF ZAMRA REPRESENTATIVES TO THE AFRICAN MEDICINES AGENCY (AMA) TECHNICAL COMMITTEES

Lusaka, 29th October, 2026…The Zambia Medicines Regulatory Authority (ZAMRA) is pleased to announce the appointment of two of its representatives to the Technical Committees of the African Medicines Agency, marking an important milestone in Zambia's contribution to strengthening medicines regulation across the African continent.

Director Laboratory Services Mr Bonaventure Chilinde has been appointed as Chairperson of the Quality Control Laboratories and Laboratory Network Technical Committee, while Acting Assistant Director Marketing Authorisation, Mr Frank Laban has been appointed as a member of the Medical Devices, Diagnostics and Emerging Technologies Technical Committee.

These appointments reflect the contribution of Zambian regulatory expertise to continental efforts aimed at strengthening regulatory systems, promoting regulatory convergence, and improving access to safe, effective and quality-assured medical products.

Speaking on the appointments, ZAMRA Director General, Mr Makomani, noted that the selection of Mr Chilinde and Mr Laban to the respective committees presents an opportunity for Zambia to contribute meaningfully to the development of strong, harmonised and effective regulatory systems across Africa.

“These appointments demonstrate the importance of collaboration and the sharing of technical expertise among African medicines regulatory authorities. Through the AMA Technical Committees, we look forward to contributing to improved quality assurance, stronger regulatory oversight and the responsible adoption of emerging medical technologies for the benefit of public health.”

The establishment of the AMA Technical Committees is an important step towards strengthening scientific cooperation, regulatory reliance and work-sharing among African countries. Their work is expected to support evidence-based regulatory decision-making and contribute to improved access to quality-assured medical products across the continent.

ZAMRA remains committed to working with the African Medicines Agency, the World Health Organization and regional partners to strengthen national and continental regulatory capacity, support pharmaceutical innovation and manufacturing, and safeguard public health.

Issued by:

The Public Relations Unit
Zambia Medicines Regulatory Authority (ZAMRA)